

Protalix BioTherapeutics, Inc.

(PLX: NYSE)

PLX: New CFO to Take the Reins

The valuation employs a net present value (NPV) approach and a 15% discount rate. Our model recognizes Elfabrio's approval in Fabry Disease in the United States and the EU and assigns 100% probability of success to it and Elelyso following US and European approval. The model includes contributions from global commercialization.

Current Price (8/14/2025)

\$1.52

Valuation

\$13.00

OUTLOOK

Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to produce therapeutic proteins for global markets. The company has two commercialized products, Elelyso that is marketed by Fiocruz in Brazil & Pfizer in the rest of the world for Gaucher Disease and Elfabrio which was approved in May 2023. Chiesi Rare Disease will commercialize Elfabrio globally.

Protalix has additional candidates in earlier stages of development including PRX-115 for the treatment of refractory gout and PRX-119, a long action DNase I for the treatment of NETs-related diseases.

Elfabrio was approved in Europe and the United States in early May 2023 and continues to be approved elsewhere. The product can fill an unmet need with several improvements over the market leader and is expected to command a premium vs. existing products. Elelyso should show moderate growth over the next quarters as partners continue their commercialization efforts. Profits from revenue generating products are expected to be invested in new candidates in coming years.

SUMMARY DATA

52-Week High	\$3.10
52-Week Low	\$0.89
One-Year Return (%)	54.7
Beta	0.0
Average Daily Volume (sh)	835,856

Risk Level

Above Average

Type of Stock

Small-Growth

Industry

Med-Biomed/Gene

Shares Outstanding (mil)	79.7
Market Capitalization (\$mil)	121.1
Short Interest Ratio (days)	5.8
Institutional Ownership (%)	14.7
Insider Ownership (%)	10.5

Annual Cash Dividend	\$0.00
Dividend Yield (%)	0.00

5-Yr. Historical Growth Rates	
Sales (%)	-0.5
Earnings Per Share (%)	N/A
Dividend (%)	N/A

P/E using TTM EPS	21.7
P/E using 2025 Estimate	6.9
P/E using 2026 Estimate	2.1

Zacks Rank	N/A
------------	-----

ZACKS ESTIMATES

Revenue

(In millions of USD)

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2024	\$3.7 A	\$13.5 E	\$18.0 A	\$18.2 A	\$53.4 A
2025	\$10.1 A	\$15.7 A	\$18.2 E	\$15.3 E	\$59.2 E
2026					\$119.4 E
2027					\$161.5 E

Earnings per Share

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2024	-\$0.06 A	-\$0.03 A	\$0.04 A	\$0.08 A	\$0.04 A
2025	-\$0.05 A	\$0.00 A	\$0.07 E	\$0.03 E	\$0.21 E
2026					\$0.74 E
2027					\$1.15 E

WHAT'S NEW

Second Quarter 2025 Financial and Operational Review

Protalix BioTherapeutics, Inc. (NYSE: PLX) announced 2Q:25 financial and operational results in an August 14th, 2025 press release and in its Form 10-Q filing. The reports were followed by a conference call which discussed recent achievements, clinical updates and financial performance. During the second quarter, Protalix generated overall revenue growth which was driven by higher sales of Elfabrio partially offset by a decline in Elelyso sales. Management reiterated its intent to launch the PRX-115 trial in the second half and enroll the first patient before year end. Protalix will gain a new CFO, Gilad Mamlok, who will take over from Eyal Rubin later this month. Other milestones since our last update include participation in investor conferences and addition of Protalix to the Russell 2000 and 3000 indices.

Management provided detail on how sales are recognized for the company with bulk orders taking place at irregular intervals. Ordering patterns are expected to be volatile until demand characteristics stabilize and market share gradually grows. Protalix did not provide any revenue guidance for the next quarters but did highlight its expectations that it can reach \$100 million in royalty revenues by 2030 based on the 15% to 20% market share of the Fabry market that it expects to own.

Financial results for the quarter ending June 30th, 2025, compared to the same quarter in the prior year:

- Revenues were \$15.7 million, up 16% from \$13.5 million attributable to an increase in sales of Elfabrio to Chiesi partially offset by a decline in Elelyso sales. Sales to Pfizer were \$5.6 million, down by about \$1.2 million and sales to Brazil of \$0.0 million due to timing of orders;
- Cost of revenue was \$5.8 million vs. \$9.5 million reflecting a decrease in Elelyso volumes;
- Research and development expenses doubled to \$6.0 million from \$3.0 million. Higher salary, subcontractor related expenses which supported the advancement of PRX-115 were the drivers for the change;
- Selling, general and administrative expenses were down 25% to \$2.6 million compared to \$3.5 million on a reduction in salary and related expenses as well as lower selling expenses;
- Net financial expense was \$511,000 compared to (\$155,000). The increase in financial expenses came from exchange rate costs and lower interest income on bank deposits;
- Income tax expense of \$497,000 compared to (\$69,000);
- Net income was \$164,000 vs a net loss of (\$2.2) million, or \$0.00 per share versus (\$0.03) per share;

The cash and equivalents balance on June 30th, 2025 totaled \$33.4 million versus \$34.8 million at the end of 2024. During 1H:25, Protalix generated \$9.2 million from the sale of common stock and exercise of warrants and options.

Chief Financial Officer (CFO) Transition

A July 21st [press release](#) announced that the CFO role at Protalix would transition from Eyal Rubin to Gilad Mamlok. The change caps a six-year term for Mr. Rubin who began at Protalix in 2019. Mr. Mamlok will be appointed senior vice president and CFO effective August 24, 2025. As shared in the announcement, Mr. Mamlok is an experienced financial executive with three decades of experience in healthcare and technology companies. He has an extensive background in capital markets transactions, mergers and acquisitions, business development and investor relations as well as corporate governance matters. Most recently, he served as the Chief Financial Officer of TytoCare, a privately-held company in the remote healthcare space. Prior to his role at TytoCare, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.

Milestones

- Chiesi gives multiple Fabry and Elfabrio presentations at WORLDSymposium Meeting – February 2025
- [Participation](#) in BIO CEO & Investor Conference – February 2025
- [Fabry Disease Presentations](#) (Chiesi) at the World Symposium Research Meeting – March 2025
- [iAccess Alpha investor conference](#) attendance – March 2025
- [Participation](#) in the H.C. Wainwright BioConnect Conference – May 2025
- [Addition](#) of Protalix to the Russell 2000 and 3000 Indices June 2025
- [Appointment](#) of Gilad Mamlok as CFO – August 2025
- Ongoing enrollment in Japanese RISE study (Elfabrio) - 2025
- Pediatric FLY study for Fabry disease (Elfabrio) - 2025
- Initiate Phase II study for PRX-115 in gout – 2H:25
- Enrollment of first patient in PRX-115 Phase II gout study – 4Q:25
- Topline results from PRX-115 Phase II study - 2027

Summary

Protalix reported its second quarter 2025 results, reporting overall year over year growth driven by Elfabrio sales which were tempered by a decline in Eleyso sales. Both of Protalix' products are vulnerable to volatile ordering patterns as their customers buy in bulk and work down inventories. We expect that Elfabrio, once it reaches greater penetration will be more predictable quarter to quarter at which time we expect management will provide guidance to analysts.

It has been a quiet summer at Protalix with participation in investor conferences, addition to Russell indices and an upcoming transition of CFO making up the newsworthy events since our previous update. We continue to be optimistic on Protalix' prospects as it has exposure to a multi-billion dollar market and offers a product which addresses many of the shortcomings of competing Fabry disease treatments. We reiterate our updated valuation of \$13 per share.

PROJECTED FINANCIALS

Protalix BioTherapeutics, Inc. - Income Statement¹


Protalix Biotherapeutics	2024 A	Q1 A	Q2 A	Q3 E	Q4 E	2025 E	2026 E	2027 E
Total Revenues (\$US '000)	\$53,399	\$10,113	\$15,658	\$18,170	\$15,260	\$59,201	\$119,464	\$161,594
YOY Growth	-18%	170%	16%	1%	-16%	11%	102%	35%
Cost of Revenues	\$24,319	\$8,180	\$5,870	\$6,600	\$6,600	\$14,726	\$20,661	\$25,135
Research & Development	\$12,970	\$3,475	\$5,992	\$3,600	\$3,800	\$16,867	\$20,250	\$20,250
Selling, General & Admin	\$12,193	\$2,603	\$2,624	\$2,848	\$3,000	\$11,075	\$14,500	\$15,650
Income from operations	\$3,917	(\$4,145)	\$1,172	\$5,122	\$1,860	\$16,533	\$64,054	\$100,559
Operating Margin	7%	-41%	7%	28%	12%		54%	62%
Financial Expenses	\$1,062	\$6	\$783	\$6	\$6	\$801	\$25	\$25
Financial Income	(\$1,299)	(\$419)	(\$272)	(\$285)	(\$277)	(\$1,253)	(\$600)	(\$600)
Pre-Tax Income	\$4,154	(\$3,732)	\$661	\$5,401	\$2,131	\$16,985	\$64,629	\$101,134
Provision for Income Tax	\$1,222	(\$113)	\$497	\$0	\$0	\$0	\$3,231	\$5,057
Tax Rate	29.4%	0.0%	0.0%	0.0%	0.0%	0.0%	5.0%	5.0%
Net Income	\$2,932	(\$3,619)	\$164	\$5,401	\$2,131	\$16,985	\$61,397	\$96,077
Net Margin	5%	-36%	1%	30%	14%	29%	51%	59%
Reported EPS	\$0.04	(\$0.05)	\$0.00	\$0.07	\$0.03	\$0.21	\$0.74	\$1.15
Diluted Shares Outstanding	81,057	76,612	81,272	81,500	82,000	80,346	82,500	83,220

Source: Company Filing // Zacks Investment Research, Inc. Estimates

¹ Financial statement information presents data as originally reported.

HISTORICAL STOCK PRICE

Protalix BioTherapeutics, Inc. – Share Price Chart²



² Source: Zacks Research System

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. This research report was prepared under the aforementioned engagement.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.